2015
DOI: 10.1097/01.hjh.0000469822.23048.ab
|View full text |Cite
|
Sign up to set email alerts
|

Blood Pressure Reduction with Telmisartan, but not Valsartan, in Angiotensinogen G-217A Polymorphism Hypertensive Patients

Abstract: Initial anti-hypertensive treatment should start off with low dose, and increased gradually till desired BP achieved. If this is inadequate in controlling BP, a combination therapy can be used. Drug trials in pediatrics are more difficult to conduct; nevertheless, it is important to be mindful of potential adverse side effects, drug interactions, and possibly different pharmacokinetics of anti-hypertensives in children. Achieving good control of BP in children is important to avoid end-organ damage and to prev… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles